Georgetown University Lombardi Cancer Center Support Grant

描述（由申请人提供）：乔治城隆巴迪综合癌症中心（LCCC）的使命是通过将科学发现、专家和富有同情心的患者护理、优质教育和与社区的合作关系联系起来，在cura personalis（“关心整个人”）原则的指导下，预防、治疗和治愈癌症。LCCC由医学肿瘤学家和免疫治疗专家Louis M. Weiner医学博士领导，并得到副主任Michael B. Atkins医学博士、六位副主任（ADs）和LCCC临床网络代表Sandra M. Swain的支持。四个研究项目——乳腺癌、癌症预防与控制、实验治疗学和分子肿瘤学——开展高影响力的研究，得到9个共享资源的支持。LCCC有91个成员，目前每年总共有2870万美元的同行评审（1850万美元的NCI）癌症资助（直接成本），从2009年到2012年，产生了1100篇同行评审的癌症相关出版物；其中32%涉及内部和/或项目间合作，53%涉及外部合作。2012年，LCCC安排了244名患者进行介入性临床试验（占新患者的13%）。值得注意的成就包括：1)发现了一种用于上皮细胞重编程的变革性方法，并可快速转化为临床试验；2)开发使能工具，如用于药物再利用的新型计算建模和集成信息平台；3)基础发现（基因组不稳定的新机制；尤文氏肉瘤的转录靶向；EGFR网络中的耐药决定因素）；4)领导高影响力的临床试验(例如，评估帕妥珠单抗在乳腺癌中的作用

DESCRIPTION (provided by applicant): The mission of the Georgetown Lombardi Comprehensive Cancer Center (LCCC) is to prevent, treat and cure cancers by linking scientific discovery, expert and compassionate patient care, quality education, and partnership with the community, guided by the principle of cura personalis ("care for the whole person"). LCCC is led by Director Louis M. Weiner, MD, a medical oncologist and immunotherapy expert, with the support of Deputy Director Michael B. Atkins, MD, six Associate Directors (ADs) and Sandra M. Swain, LCCC's clinical network representative. Four Research Programs-Breast Cancer, Cancer Prevention and Control, Experimental Therapeutics and Molecular Oncology-conduct high-impact studies supported by nine Shared Resources. LCCC has 91 members, with a current annual total of $28.7M in peer-reviewed ($18.5M NCI) cancer-focused funding (direct costs), resulting in 1,100 peer-reviewed cancer-related publications from 2009-2012; 32% of which involved intra- and/or interprogrammatic collaborations, and 53% of which involved external collaborations. In 2012, LCCC placed 244 patients on interventional clinical trials (13% of new patients). Notable accomplishments include: 1) discovery of a transformative methodology for epithelial cell reprogramming with rapid translation into clinical trials; 2) development of enabling tools such as novel computational modeling for drug repurposing and integrated informatic platforms; 3) basic discovery (novel mechanisms for genomic instability; transcriptional targeting in Ewing sarcoma; resistance determinants in the EGFR network); 4) leadership of high-impact clinical trials (e.g., evaluation of pertuzumab in breast cancer, role of bendamustine in follicular lymphoma); 5) national collaborative modeling research informing screening mammography guidelines and 6) operational enhancements that include creation of the MedStar Georgetown Cancer Network to expand clinical research in LCCC's catchment area under the direction of recent recruit, Giuseppe Giaccone, MD, PhD (AD, Clinical Research); a reorganization of clinical trial management and regulatory activities to better support the Network; and the continued development of community outreach and research sites in the poorest wards of the District of Columbia.